Research Institute, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537-8511, Japan.
Clin Exp Metastasis. 2011 Jun;28(5):427-35. doi: 10.1007/s10585-011-9381-0. Epub 2011 Mar 5.
Intratumor heterogeneity-heterogeneity of cancer cells within a single tumor-is considered one of the most problematic factors of treatment. Genetic heterogeneity, such as in somatic mutations and chromosome aberrations, is a common characteristic of human solid tumors and is probably the basis of biological heterogeneity. Using mutations in APC, TP53 and KRAS as markers to identify distinct colorectal cancer subpopulations, we analyzed a total of 42 primary colorectal cancer tissues and six paired liver metastases with multipoint microsampling, which enabled analysis of mutation patterns and allelic imbalances with a resolution of 0.01 mm(2) (about 200 cells). There was usually more than one subpopulation in each primary tumor. Only two of 15 (13.3%) cases with three gene mutations and eight of 27 (29.6%) cases with two gene mutations had a single subpopulation. Cells with mutations in all of the examined genes usually constituted the major population. Multipoint microsampling of six primary and metastatic tumor pairs revealed that the majority of discrepancies in mutation patterns found with the bulk tissue analysis were due to loss of subpopulations in the metastatic tissues. In addition, multipoint microsampling uncovered substantial changes in subpopulations that were not detected with bulk tissue analysis. Specifically, the proportion of KRAS mutation-negative subpopulations increased in the metastatic tumors of four cases. Because KRAS mutation status is linked to cetuximab/panitumumab efficacy, subpopulation dynamics could lead to differences in response to cetuximab/panitumumab in primary versus metastatic tumors.
肿瘤内异质性——即单个肿瘤内的癌细胞异质性——被认为是治疗中最具挑战性的因素之一。遗传异质性,如体细胞突变和染色体异常,是人类实体瘤的共同特征,可能是生物学异质性的基础。我们使用 APC、TP53 和 KRAS 突变作为标记物来识别不同的结直肠癌细胞亚群,对总共 42 份原发性结直肠癌组织和 6 对配对肝转移组织进行多点微采样分析,这使得我们能够以 0.01mm²(约 200 个细胞)的分辨率分析突变模式和等位基因失衡。每个原发性肿瘤中通常存在不止一个亚群。在存在三种基因突变的 15 个病例中,仅有 2 个(13.3%)存在单一亚群;在存在两种基因突变的 27 个病例中,仅有 8 个(29.6%)存在单一亚群。通常,所有检测基因发生突变的细胞构成了主要群体。对 6 对原发性和转移性肿瘤的多点微采样显示,在使用组织块分析发现的突变模式中的大多数差异是由于转移组织中丢失了亚群。此外,多点微采样还揭示了组织块分析未检测到的亚群的实质性变化。具体而言,在 4 个病例的转移性肿瘤中,KRAS 突变阴性亚群的比例增加。因为 KRAS 突变状态与西妥昔单抗/帕尼单抗的疗效相关,所以亚群动力学可能导致原发性肿瘤与转移性肿瘤对西妥昔单抗/帕尼单抗的反应不同。